Modulation of melphalan and cisplatin cytotoxicity in human ovarian cancer cells resistant to alkylating drugs

Anti-Cancer Drugs

Volumn 8, Issue 5, 1997, Pages 509-516

  Gornati, Daniela ^a   Zaffaroni, Nadia ^a   Villa, Raffaella ^a   De Marco, Cinzia ^a   Silvestrini, Rosella ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Alkylating drugs; Cisplatin; Melphalan; OAW42; OAW42MER

Indexed keywords

CISPLATIN; DIMETHYL SULFOXIDE; FLUDARABINE PHOSPHATE; FLUNARIZINE; MEGLUMINE; MELPHALAN; MITOMYCIN C; NIMODIPINE; TOPOTECAN; VERAPAMIL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOPATHOGENIC EFFECT; DNA CLEAVAGE; DNA REPAIR; DRUG DNA INTERACTION; DRUG EFFECT; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL;

EID: 0030812008     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199706000-00014     Document Type: Article

References (31)

1. Sarosy G, Leyland-Jones B, Soochan P, Cheson BD. The systemic administration of intravenous melphalan. J Clin Oncol 1988; 6: 1768-82.
2. Redwood WR, Colvin M. Transport of melphalan by sensitive and resistant L1210 cells. Cancer Res 1980; 40: 1144-9.
3. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994; 54: 4313-20.
4. Clapper ML, Buller AL, Smith TM, Tew KT. Glutathione S-transferases in alkylating agent resistant cells. In: Mantle TJ, Pickett CB, Hayes JD, eds. Glutathione S-transferases and carcinogenesis. London: Taylor & Francis 1987: 213-24.
5. Parsons PG. Dependence on treatment time of melphalan resistance and DNA cross-linking in human melanoma cell lines. Cancer Res 1984; 44: 2773-8.
6. Batist G, Torres-Garcia S, Demuys J-M, et al. Enhanced DNA cross-link removal: the apparent mechanism of resistance in a clinically relevant melphalan-resistant human breast cancer cell line. Mol Pharmacol 1989; 36: 224-30.
7. Liu LF. DNA topoisomerase poisons as antitumour drugs. Annu Rev Biochem 1989; 58: 351-5.
8. Burns III HA, Hanauske A-R, Johnson RK, et al. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 1992; 84: 1816-20.
9. Hahn G, Van Kersen I, Silvestrini B. Inhibition of the recovery from potentially lethal damage by lonidamine. Br J Cancer 1984; 50: 657-60.
10. Silvestrini R, Zaffaroni N, Villa R, Orlandi L, Costa A. Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells. Int J Cancer 1992; 52: 813-7.
11. Averill-Bates A, Courtemanche B. The effect of hyperthermia and verapamil on melphalan cytotoxicity and transport in multidrug-resistant chinese hamster ovary cells. Radiat Res 1995; 143: 17-25.
12. Castellino SM, Friedman HS, Elion GB, et al. Flunarizine enhancement of melphalan activity against drug-sensitive/resistant rhabdomyosarcoma. Br J Cancer 1995; 71: 1181-7.
13. Wilson AP. Characterization of a cell line derived from the ascites of a patient with papillary serous cystadenocarcinoma of the ovary. J Natl Cancer Inst 1984; 72: 513-21.
14. Britten RA, Warenius HM, White R, Browning PGW, Green JA. Melphalan resistant human ovarian tumour cells are cross-resistant to photons, but not to high LET neutrons. Radiother Oncol 1990; 18: 357-63.
15. Kohn KW. DNA as a target in cancer chemotherapy: measurement of macromolecular DNA damage produced in mammalian cells by anticancer agents and carcinogens. Methods Cancer Res 1979; 16: 291-8.
16. Kohn KW, Ewig RAG, Erickson LC, Zwelling LA. Measurement of strand breaks and cross-links by alkaline elution. In: Friedberg EC, Hanawalt PC, eds. DNA repair A laboratory manual of research procedures. New York: Marcel Dekker 1981: 379-401.
17. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol chloroform extraction. Anal Biochem 1987; 162: 156-9.
18. Singh SV, Xu HB, Jani JP, et al. Mechanism of cross-resistance to cisplatin in a mitomycin C-resistant human bladder cancer cell line. Int J Cancer 1995; 61: 431-6.
19. Page JD, Husain I, Chancy SG, Sancar A. In vitro repair of cisplatin-DNA adducts by a defined enzyme system. In: Nicolini M, ed. Platinum and other metal coordination compounds in cancer chemotherapy. Boston: Martinus Nijhoff 1988: 115-26.
20. Taverna P, Hansson J, Scanlon KJ, et al. Gene expression in X-irradiated human tumor cell lines expressing cisplatin resistance and altered DNA repair capacity. Carcinogenesis 1994; 15: 2053-6.
21. Dabholkar M, Bostick-Bruton F, Reed E. ERCC1 and ERCC2 expression in fresh human tumor tissues. J Natl Cancer Inst 1992; 84: 1512-7.
22. Geleziunas R, McQuillan A, Malapetsa A, et al. Increased DNA synthesis and repair-enzyme expression in lymphocytes from patients with chronic lymphocytic leukemia resistant to nitrogen mustards. J Natl Cancer Inst 1991; 83: 557-64.
23. Weber C, Salazar EP, Stewart SA, Thompson LH. Molecular cloning and biological characterization of a human gene, ERCC2, that corrects the nucleotide excision repair defect in CHO UV5 cells. Mol Cell Biol 1988; 8: 1137-46.
24. Damia G, Imperatori L, Stefanini M, D'Incalci M. Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents. Int J Cancer 1996; 66: 779-83.
25. Crumplin GC. The involvement of DNA toposomerase in DNA repair and mutagenesis. Carcinogenesis 1981; 2: 157-60.
26. Roshe KW, Brann TW, Holden SA, Teicher BA, Frei E. Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro. Cancer Chemother Pharmacol 1989; 25: 32-6.
27. Ning S, Hahn GM. Cytotoxicity of lonidamine alone and in combination with other drugs against murine RIF-1 and human HT1080 cells in vitro. Cancer Res 1990; 50: 7867-70.
28. Teicher BA, Herman TS, Holden SA, Epelhaum R, Liu S, Frei E. Lonidamine as a modulator of akylating agent activity in vitro and in vivo. Cancer Res 1991; 51: 780-4.
29. Bearzatto A, Saino A, Zaffaroni N, Costa A, Santi S. Nimodipine as a modulator of resistance to doxorubicin in human colon-adenocarcinoma cells: a comparative study with verapamil. Int J Oncol 1996; 9: 57-63.
30. Rogan AM, Hamilton TC, Young RC, Kelecker RW, Ozols RF. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 1984; 224: 994-6.
31. Robinson BA, Clutterbuck RD, Millar JL, McElwain TJ. Verapamil potentiation of melphalan cytotoxicity and cellular uptake in murine fibrosarcoma and bone marrow. Br J Cancer 1985; 52: 813-22.